Items Tagged ‘letrozole’

October 26th, 2016

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer

By

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The interim results from a large clinical trial presented at the 2016 European Society for Medical Oncology (ESMO) meeting and published in the […]

View full entry

Tags: 2016, Breast Cancer, ESMO, Femera, hormone-receptor positive, HR+ metastatic, letrozole, Metastatic Breast Cancer, MONALEESA-2 clinical, News, ribociclib LEE011


October 28th, 2015

The Type of Breast Cancer Determines Effectiveness of Different Hormonal Therapies

By

According to the results of a recent study published in the Journal of Clinical Oncology, women with certain subtypes of hormone-positive breast cancer appear to benefit differently when treated with hormone therapy. Hormone-positive breast cancer refers to breast cancer that is stimulated to grow from the female hormone, estrogen. Therefore, a standard treatment component for […]

View full entry

Tags: AI, anti-estrogen agent, aromatase inhibitors, Breast Cancer, Femara, hormone-positive breast cancer, IDC, ILC, letrozole, News, tamoxifen


February 27th, 2015

Palbociclib/Letrozole Improves Outcomes of Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer

By

The results of the phase II PALOMA-1/TRIO-18 trial were recently reported in The Lancet Oncology and suggest that the addition of Ibrance® (palbociclib) to Femara® (letrozole) delayed the time to cancer progression when used as first-line treatment for advanced breast cancer in postmenopausal women with estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)-negative disease. […]

View full entry

Tags: Breast Cancer, ER-positive, estrogen receptor-positive, Femara, HER-2 negative, human epidermal growth factor receptor-negative, Ibrance, kinase inhibitor, letrozole, Metastatic Breast Cancer, News, palbociclib